SKINCARE specialist Evocutis expects to see a commercial benefit this year as health and cosmetic companies start adopting its research.
The Wetherby-based company said revenues more than doubled to £344,000 in the six months to January 31, reflecting an improved performance across the group.
Adjusted operating losses were reduced from £542,000 to £346,000.
Evocutis said significant revenues are being generated from its skin equivalent model LabSkin and its clinical operations and microbiology services.
LabSkin is an animal-replacement technology that emulates living skin tissue.
The group, which changed its name from Syntopix last October, said it has completed the integration of its recent acquisition Leeds Skin.
Chief executive Dr Stephen Jones said: “The significant increase in revenue over the first half of the year reflects the progress we are now starting to make in commercialising our new and existing technology platforms.
“We have continued to invest in the development and validation of these platforms and we fully expect to realise the commercial benefit of these initiatives throughout the next 12 months.
“This is a very exciting time for Evocutis as the group continues to attract a very healthy interest from the skin care industry for its unique technology offerings.”
Evocutis offers antimicrobial and dermatological expertise to the cosmetic, consumer healthcare and pharmaceutical industries.
It combines research for laboratory testing, advanced skin models and clinical testing to help develop skin care products and ingredients.
“Through research and testing we enable our clients to advance the discovery of skin care products that actually work,” said Dr Jones.